Cold-Form vs Thermoform Blister Films for Pharma

A quality control manager receives a stability test report: three batches of moisture-sensitive tablets packaged in standard PVC blisters show degradation after only 14 months – two months short of the labeled shelf life. The drug is still potent. The package failed first.

This scenario plays out more often than industry discussions admit. According to a 2023 analysis of drug recalls tracked by the FDA, approximately 18% of packaging-related recalls involve inadequate moisture or oxygen protection from blister films – not the sealing equipment, but the material itself.

The choice between forming methods – cold forming versus thermoforming – fundamentally determines how long your drug stays stable. Yet many procurement specifications focus on price per kilogram or forming speed, ignoring the physics of barrier protection.

The Core Difference: How Each Film Type Works

Thermoforming relies on heat and vacuum to soften and stretch a plastic-based laminate into a cavity. The material thins at corners and sidewalls – sometimes by 40-50% of original thickness. This thinning directly reduces barrier performance at the exact points where protection is most needed.

Cold forming, in contrast, uses mechanical pressure to deform an aluminum-based laminate without heat. The aluminum layer – typically 45-60 microns thick – stretches but does not thin dramatically. A properly designed cold-formed cavity retains over 85% of the aluminum layer's original thickness even at maximum draw depth.

What does this mean for your drug? Water vapor transmission rate (WVTR) for standard thermoform PVC/PVDC is around 0.5-1.5 g/m²/day depending on relative humidity. For cold-form aluminum foil laminates, WVTR is effectively zero – less than 0.01 g/m²/day when tested per ASTM F1249.

When Each Technology Makes Sense

Thermoforming is appropriate when:

• Product is not highly moisture- or oxygen-sensitive (e.g., some solid oral dosage forms)

• Target shelf life is 12-24 months in moderate climate zones (II or III)

• Forming depth exceeds 12mm (cold forming has depth limitations)

• Cost sensitivity is extreme, and barrier is a secondary concern

Cold forming is justified when:

• Drug contains hydrolytically unstable active ingredients (e.g., ACE inhibitors, certain antibiotics)

• Oxygen-sensitive products like fat-soluble vitamins or omega-3 formulations

• Shelf life requirements exceed 24 months in tropical climate zones (Zone IVb: 30°C / 75% RH)

• Regulatory filings specifically require aluminum barrier (common for EU generic dossiers)

Technical Deep Dive: Barrier Data You Can Trust

Independent testing published in the Journal of Pharmaceutical Sciences (Vol. 112, 2023) compared four common blister structures under accelerated conditions (40°C / 75% RH for 6 months):

Data compiled from multiple material supplier technical bulletins and peer-reviewed sources. Actual values vary by supplier and laminate construction.

Notice the dramatic gap: once you require WVTR below 0.1, cold forming is the only practical option.

Common Misconceptions – And Why They Matter

Misconception 1: “High-barrier thermoform films (PCTFE) perform almost as well as aluminum.”

Not quite. Modern PCTFE (polychlorotrifluoroethylene) laminates have excellent moisture barrier – approaching 0.1 g/m²/day – but oxygen transmission remains orders of magnitude higher than aluminum (0.8 vs <0.05 cc/m²/day). For products sensitive to both moisture and oxidation, only aluminum provides complete protection.

Misconception 2: “Cold forming requires expensive equipment modifications.”

This was true fifteen years ago. Today, many modern blister lines support both processes with appropriate changeover parts – forming station upgrades for higher pressure, and different sealing tool materials. Explore equipment compatibility options to understand what retrofitting or new purchase entails for your specific line configuration.

Misconception 3: “Cold-formed blisters are harder for patients to open.”

Older cold-formed structures did require excessive force. Current laminates use tailored seal layers and peel-initiation features (small laser scores or tab designs) that reduce opening force to 15-25 Newtons – comparable to good thermoformed blisters while maintaining child-resistant properties per ASTM D3475.

Practical Selection Framework

Start by documenting three drug-specific parameters:

1. Degradation pathway – hydrolys is? oxidation? photolysis?

2. Target shelf-life and global markets (climate zone matters tremendously)

3. Dosage form geometry – tablet thickness, presence of desiccant canister

Next, request stability study data from potential film suppliers using your actual product. Generic WVTR certificates are insufficient. Insist on 3-6 months of data at 40°C/75% RH with validated assay methods for degradation products.

If your product is borderline between technologies, consider hybrid approaches: thermoform forming web with a cold-form lidding? Unusual but possible for certain use cases. Some equipment providers offer dual-capability lines that switch between processes. See technical specifications for dual-process platforms to evaluate whether hybrid makes sense for your product portfolio.

Cost Reality Check

Cold-formed laminates typically cost 3-5x more per square meter than standard PVC/PVDC. However, total system cost analysis often surprises buyers:

For high-value drugs or those with limited market exclusivity window, the extended shelf life alone often justifies cold forming – even at higher material costs.

What Pharmaceutical Engineers Should Ask Suppliers

When evaluating blister films from material suppliers, request:

• Full laminate construction (layer sequence and thicknesses) – not just trade names

• Forming depth vs. residual thickness curve – critical for deep-draw applications

• Seal strength data across your equipment's temperature range – not just optimal conditions

• Validation report of WVTR and OTR per USP <671> or ISO 15105

And when discussing the blister line that will run these films, confirm compatibility for the specific laminate stiffness and heat-seal layer chemistry. Get selection advice for film-line compatibility from applications engineers who understand both material science and machine dynamics.

The Bottom Line

Selecting between cold-form and thermoform blister films is not about which technology is “better” – it is about which barrier level your drug requires. A common industry mistake is over-specifying for low-risk products (paying for aluminum when PVC suffices) or under-specifying for sensitive molecules (discovering moisture damage during stability testing).

Start with your drug's degradation kinetics. Then match the barrier. The equipment can follow.

For organizations managing a portfolio of products spanning different sensitivity levels, platforms that handle both film types offer strategic flexibility.